Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. ATOS
ATOS logo

ATOS Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Atossa Therapeutics Inc (ATOS) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
2.280
1 Day change
7.55%
52 Week Range
19.350
Analysis Updated At
2026/07/03
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

ATOS is not a good buy right now for a beginner long-term investor with $50,000-$100,000 who is unwilling to wait for an ideal entry. The setup is mixed: short-term momentum has improved slightly, but the broader trend remains bearish and there is no strong catalyst or proprietary buy signal to justify an immediate purchase. If the goal is long-term capital deployment, this is better treated as a watchlist name rather than an immediate buy.

Technical Analysis

Current price is 2.10, essentially flat versus the 2.12 prior close, with the session showing some intraday strength but no follow-through. MACD histogram is positive and expanding, which is a short-term bullish sign. However, RSI_6 at 46.06 is neutral, and the moving averages remain bearish with SMA_200 > SMA_20 > SMA_5, indicating the longer-term trend is still down. Key levels: pivot 1.937, resistance 2.124 and 2.24, support 1.75 and 1.634. The stock is sitting right near first resistance, so upside is not confirmed yet. The 1-day, 1-week, and 1-month pattern probabilities are also weak to slightly negative, suggesting limited momentum for a clean entry.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Options sentiment is strongly bullish on paper, with a very low open interest put-call ratio of 0.07 and zero put volume reported today versus 26 call volume. That implies call-heavy positioning and near-term optimism. However, total volume is light and the stock has very high implied volatility (30d IV 132.3) and historical volatility 166.64, so the options market is signaling speculation rather than strong conviction. IV percentile is high at 85.32, meaning options are relatively expensive.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
7
Buy
3

Positive Catalysts

  • ["MACD histogram is positive and expanding, showing short-term momentum improvement.", "Options positioning is call-heavy, with very low put-call ratios.", "Price is trading near the first resistance level, so a breakout above 2.124 could improve the trend."]

Neutral/Negative Catalysts

  • ["No news in the recent week, so there is no fresh catalyst driving the stock.", "No recent congress trading data.", "No significant hedge fund or insider buying trends; both are neutral.", "Longer-term technical trend remains bearish with SMA_200 > SMA_20 > SMA_5.", "No AI Stock Picker signal and no recent SwingMax signal.", "Short-term pattern analysis suggests slightly negative expected returns over the next day and month."]

Financial Performance

Latest quarter financials were not available due to a data error, so there is no reliable recent quarterly growth assessment from the provided snapshot. Because of that, there is no confirmed evidence here of improving revenue or earnings trends in the latest reported season.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target trend data was provided, so there is no visible evidence of improving Wall Street sentiment. Based on the available data, the pros are limited to call-heavy options positioning and short-term MACD improvement, while the cons are the lack of catalysts, bearish longer-term trend, and absence of notable analyst or insider support. Overall Wall Street evidence in this snapshot is neutral to cautious rather than strongly bullish.

Wall Street analysts forecast ATOS stock price to rise
4 Analyst Rating
Wall Street analysts forecast ATOS stock price to rise
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 2.120
sliders
Low
7
Averages
18.33
High
40
Current: 2.120
sliders
Low
7
Averages
18.33
High
40
H.C. Wainwright
NULL -> Buy
maintain
$7 -> $25
AI Analysis
2026-03-26
Reason
H.C. Wainwright
Price Target
$7 -> $25
AI Analysis
2026-03-26
maintain
NULL -> Buy
Reason
H.C. Wainwright adjusted the firm's price target on Atossa Therapeutics to $25 from $7 and keeps a Buy rating on the shares. The firm cites the company's 1-for-15 reverse stock split for the change.
Craig-Hallum
Craig-Hallum
Buy
downgrade
$35 -> $10
2026-02-12
Reason
Craig-Hallum
Craig-Hallum
Price Target
$35 -> $10
2026-02-12
downgrade
Buy
Reason
Craig-Hallum lowered the firm's price target on Atossa Therapeutics to $10 from $35 and keeps a Buy rating on the shares. The firm cites Atossa's decision to pause Z-endoxifen's development in metastatic breast cancer to prioritize other breast cancer settings and DMD. Z-endoxifen's other breast cancer studies remain ongoing including the I-SPY and EVANGELINE studies in neoadjuvant breast cancer, where data updates are expected later this year. The year-end 2025 cash balance of about $40M provides at least one year of runway, argues Craig-Hallum.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for ATOS
Unlock Now

People Also Watch